Literature DB >> 2161717

Malignant tumours of the parotid: a study of 76 patients.

P Marandas1, D Dharkar, A Davis, A M Leridant, L Pacheco Ojeda, C Micheau, P Wibault, G Schwaab.   

Abstract

This study presents a series of malignant parotid tumours treated at the Institut Gustave-Roussy between 1975 and 1984. The lesions represented a wide variety of histological types. Few preoperative investigations were required, management being based on histology. Effective local control requires a total parotidectomy preserving the facial nerve where possible. It should be followed by routine radiotherapy which appears to reduce the incidence of local recurrence. The rate of local recurrence also depends on the histological type. It is seen more frequently in an adenocarcinoma following a pleomorphic adenoma than in simple adenocarcinoma. Patients with inoperable disease are treated with radiotherapy alone as chemotherapy has not so far been effective. Percentage 5-year survival for the three most common tumour types is as follows: adenocarcinoma: 49; adenoid cystic carcinoma: 83, and mucoepidermoid carcinoma: 75.

Entities:  

Mesh:

Year:  1990        PMID: 2161717     DOI: 10.1111/j.1365-2273.1990.tb00441.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  2 in total

1.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

2.  Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells.

Authors:  Tomoki Sumida; Ryuichi Murase; Akiko Onishi-Ishikawa; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  BMC Cancer       Date:  2013-03-22       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.